He emphasized that he'd need to know more about the woman to make a diagnosis but implied the need to be cautious in distinguishing between the two disorders and determining the influence of GLP-1 receptor agonists in both contexts
has received funding from the Wellcome Trust (221604/Z/20/Z) and Barts Charity Grants (MRC0215, G-002145)
How fast will I see results with semaglutide
The general evidence for probiotic benefits in GI health is substantial, and the specific mechanistic connections to GLP-1 therapy are promising
Ileus or bowel obstruction Gallbladder disease and gallstones Pancreatitis and pancreatic injury Dehydration , electrolyte imbalances , and kidney strain Weight loss outside expected ranges or malnutrition in some cases, including individuals using these drugs, such as Ozempic, for weight loss Vision loss and rare visual conditions such as NAION , with some plaintiffs reporting symptoms consistent with naion even before clear diagnosis Concerns over thyroid Ccell tumors noted in animal studies The lawsuits generally claim that manufacturers, including Novo Nordisk, failed to provide adequate warnings about drugs like Ozempic, promoted offlabel use for weight loss without proper risk disclosures, and did not update labels or prescriber communications quickly enough as reports of side effects and other injuries came in
Grey matter changes over time in high risk subjects developing schizophrenia